ImMucin
by Jessica Langholtz
Published: Oct 8, 2010 11:49 am
Published: Oct 8, 2010 11:49 am
| Brand Name: | ImMucin |
| Generic Name: | |
| Code Name: | |
| Company: | Vaxil BioTherapeutics |
| FDA Clinical Phase: | 1/2 |
Description:
ImMucin is a vaccine designed to stimulate the patient’s own immune system to kill cancer cells. ImMucin is a synthetic version of the important region of the MUC1 protein, which is made by more than 90 percent of common solid tumor cancers and many non-solid tumors, including multiple myeloma. ImMucin is designed to train the immune system to detect and kill cells that have MUC1 on their surface.
Clinical Trials:
For a list of clinical trials studying ImMucin for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official website for InMucin: http://www.vaxilbio.com/...
Related Articles:
- Getting To Know: Tiragolumab
- Getting To Know: TNB-383B
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma